Predictors of Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF trial

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker’s Bureau - Valfix; TherOx; Robocath; HeartFlow; Ablative Solutions; Miracor; Neovasc; Ancora; Vectorious; RCE; Cardiac Success; Elucid Bio; Occlutech; HighLife; Apollo Therapeutics; Impulse Dynamics; Amgen; Medtronic; Boehringer Ingelheim; Abiomed; Daiichi-Sankyo/Elil Lilly and Company; Adona Medical; Millennia Biopharma; Oxitope; Aria; Elixir; Abbott
• Equity/Stock(s)/Options - Ancora; Cagent; Applied Therapeutics; Biostar family of funds; SpectraWave; Orchestra Biomed; Aria; Valfix; Xenter; Cardiac Success
• Grant Support/Research Contract - Abbott Vascular; Bioventrix; V-wave; Shockwave; Cardiovascular Systems Inc.; Phillips; Biosense Webster; Vascular Dynamics; Pulnovo; Abiomed